Hanmi Science Co., Ltd.

KOSE:A008930 Stock Report

Market Cap: ₩1.9t

Hanmi Science Past Earnings Performance

Past criteria checks 2/6

Hanmi Science has been growing earnings at an average annual rate of 36.5%, while the Healthcare industry saw earnings growing at 11.3% annually. Revenues have been growing at an average rate of 10.6% per year. Hanmi Science's return on equity is 12.2%, and it has net margins of 8.2%.

Key information

36.5%

Earnings growth rate

36.8%

EPS growth rate

Healthcare Industry Growth34.2%
Revenue growth rate10.6%
Return on equity12.2%
Net Margin8.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Is Hanmi Science (KRX:008930) Using Too Much Debt?

Nov 14
Is Hanmi Science (KRX:008930) Using Too Much Debt?

Hanmi Science Co., Ltd. (KRX:008930) Looks Just Right With A 27% Price Jump

Oct 27
Hanmi Science Co., Ltd. (KRX:008930) Looks Just Right With A 27% Price Jump

Returns On Capital Are Showing Encouraging Signs At Hanmi Science (KRX:008930)

Aug 30
Returns On Capital Are Showing Encouraging Signs At Hanmi Science (KRX:008930)

Here's Why Hanmi Science (KRX:008930) Can Manage Its Debt Responsibly

Aug 13
Here's Why Hanmi Science (KRX:008930) Can Manage Its Debt Responsibly

Hanmi Science Co., Ltd. (KRX:008930) Not Flying Under The Radar

Jul 22
Hanmi Science Co., Ltd. (KRX:008930) Not Flying Under The Radar

Is Hanmi Science (KRX:008930) Using Too Much Debt?

Apr 29
Is Hanmi Science (KRX:008930) Using Too Much Debt?

Hanmi Science Co., Ltd.'s (KRX:008930) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Jan 31
Hanmi Science Co., Ltd.'s (KRX:008930) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

We Think Hanmi Science (KRX:008930) Can Stay On Top Of Its Debt

Jan 05
We Think Hanmi Science (KRX:008930) Can Stay On Top Of Its Debt

Shareholders Are Thrilled That The Hanmi Science (KRX:008930) Share Price Increased 100%

Dec 06
Shareholders Are Thrilled That The Hanmi Science (KRX:008930) Share Price Increased 100%

Revenue & Expenses Breakdown

How Hanmi Science makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A008930 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,283,652104,963244,2060
30 Jun 241,270,535117,972225,7880
31 Mar 241,276,796120,140225,6030
31 Dec 231,247,906115,122195,7110
30 Sep 231,204,102103,441924,0690
30 Jun 231,146,63987,952873,2960
31 Mar 231,085,36178,957162,0300
31 Dec 221,046,05469,210126,1040
30 Sep 221,021,32150,741925,0110
30 Jun 221,005,82851,563701,2930
31 Mar 22987,01348,3011,134,5410
31 Dec 21950,16542,942914,4820
30 Sep 21905,45354,13991,9590
30 Jun 21884,89630,54990,4150
31 Mar 21858,09127,69288,9530
31 Dec 20857,38322,60186,7100
30 Sep 20857,31814,78885,4970
30 Jun 20845,64628,29884,9210
31 Mar 20842,85331,27984,4590
31 Dec 19816,61930,74283,2200
30 Sep 19789,83616,43481,5650
30 Jun 19756,11519,06978,8250
31 Mar 19722,66416,91476,2230
31 Dec 18707,99518,02074,4040
30 Sep 18676,78327,62473,6250
30 Jun 18677,13130,01473,3910
31 Mar 18668,03630,50177,1050
31 Dec 17652,32430,06970,6260
30 Sep 17654,405-7,30968,5560
30 Jun 17650,646-12,91768,0350
31 Mar 17652,216-2,59262,2370
31 Dec 16665,2857,93864,7330
30 Sep 16766,544185,30865,0990
30 Jun 16782,644171,72462,0970
31 Mar 16791,910175,43861,1380
31 Dec 15776,629178,52162,6060
30 Sep 15655,71337,677193,7390
30 Jun 15609,54147,789314,1500
31 Mar 15565,08026,785423,0250
31 Dec 14532,88621,312519,4910
30 Sep 14446,95921,767424,3580
30 Jun 14365,34521,733343,0140
31 Mar 14292,02122,302271,6140
31 Dec 13220,3969,578209,8090

Quality Earnings: A008930 has high quality earnings.

Growing Profit Margin: A008930's current net profit margins (8.2%) are lower than last year (8.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A008930's earnings have grown significantly by 36.5% per year over the past 5 years.

Accelerating Growth: A008930's earnings growth over the past year (1.5%) is below its 5-year average (36.5% per year).

Earnings vs Industry: A008930 earnings growth over the past year (1.5%) did not outperform the Healthcare industry 7.6%.

Return on Equity

High ROE: A008930's Return on Equity (12.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 09:57
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hanmi Science Co., Ltd. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Young-Ah HanBofA Global Research
Jeehye SongGoldman Sachs
Jin Kyun LimIBK Securities Co. Ltd.